
Arpit Deepakkumar Shah
About Arpit Deepakkumar Shah
Data last updated:
Arpit Deepakkumar Shah is a Managing Director at Remus Pharmaceuticals Limited (since 2015), Director at Senores Pharmaceuticals Limited (since 2023) and Director at Ratnatris Pharmaceuticals Private Limited (since 2021), and holds 3 more current directorships. The companies operate in Trading, Pharma and Real Estate and Construction. The 5 current companies with reported revenue have a combined latest revenue of ₹1,185 Cr; the largest is Remus Pharmaceuticals Limited at ₹625 Cr (FY 2025). Earlier, Arpit Deepakkumar Shah was a Designated Partner at Sumer Enterprises Llp (from 2018).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Managing Director | 21 Sep 2015 | 2015 | ₹625 Cr (FY 2025) | Active | |
| Director | 10 Nov 2023 | 2017 | ₹418 Cr (FY 2025) | Active | |
| Director | 15 Jan 2021 | 2005 | ₹142 Cr (FY 2025) | Active | |
| Partner | 27 Jul 2023 | 2022 | ₹2.1 Lakh (FY 2026) | Active | |
| Partner | 28 Jan 2021 | 2016 | ₹85,669 (FY 2026) | Active | |
| Director | 21 Nov 2016 | 2016 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Designated Partner | 13 Aug 2018 | 2018 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Arpit Deepakkumar Shah
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Arpit Deepakkumar Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arpit Deepakkumar Shah
Arpit Deepakkumar Shah currently holds 6 directorships: Remus Pharmaceuticals Limited (Managing Director, since 21 Sep 2015, revenue ₹625 Cr (FY 2025)); Senores Pharmaceuticals Limited (Director, since 10 Nov 2023, revenue ₹418 Cr (FY 2025)); Ratnatris Pharmaceuticals Private Limited (Director, since 15 Jan 2021, revenue ₹142 Cr (FY 2025)); Newmark Properties Llp (Partner, since 27 Jul 2023, revenue ₹2.1 Lakh (FY 2026)); Calypso Hospitality Llp (Partner, since 28 Jan 2021, revenue ₹85,669 (FY 2026)); and 1 more.
Arpit Deepakkumar Shah was first appointed on 21 Sep 2015 as Managing Director at Remus Pharmaceuticals Limited. The most recent appointment on record is 10 Nov 2023 at Senores Pharmaceuticals Limited.
The 5 current companies of Arpit Deepakkumar Shah that report revenue have a combined latest revenue of ₹1,185 Cr: Remus Pharmaceuticals Limited ₹625 Cr (FY 2025); Senores Pharmaceuticals Limited ₹418 Cr (FY 2025); Ratnatris Pharmaceuticals Private Limited ₹142 Cr (FY 2025); Newmark Properties Llp ₹2.1 Lakh (FY 2026); Calypso Hospitality Llp ₹85,669 (FY 2026).
Arpit Deepakkumar Shah held 1 earlier board appointment: Sumer Enterprises Llp (Designated Partner, from 13 Aug 2018).
The current boards of Arpit Deepakkumar Shah's companies include Anar Swapnil Shah (Remus Pharmaceuticals Limited), Ashutosh Naginbhai Valani (Remus Pharmaceuticals Limited), Balwant Purohit (Remus Pharmaceuticals Limited), Bhavik Rashmikant Shah (Remus Pharmaceuticals Limited), Deval Bakulkumar Patel (Remus Pharmaceuticals Limited), Roma Vinodbhai Shah (Remus Pharmaceuticals Limited), among others.